Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

Meanwhile, new findings from cell and animal models continued to paint a kaleidoscopic picture of TREM2 function. For example, microglia making the most TREM2—the ones scientists hope to energize with ...

Their analysis of three large population studies found that age-adjusted prevalence has dropped by a whopping two-thirds over the last 40 years. In other words, every successive birth cohort has a ...

These studies led the authors to investigate whether xenon could ameliorate Alzheimer’s disease. Because Butovsky’s lab studies microglia, which carry most of the genetic risk for AD, they looked to ...

The advisory committee voted 11 to 0 on both questions in favor of the approval of donanemab. The committee recognized, correctly I think, that the data supported a modestly favorable benefit to risk ...

For decades, the U.S. Food and Drug Administration has taken a light touch to regulating diagnostic tests that use body fluids or tissues. Such assays, very much including cerebrospinal fluid and ...

While the range of therapeutic approaches is broad, several sessions kept a spotlight on amyloid immunotherapy. Here, the buzziest data came from Roche, which reported that at the highest dose yet ...

The DIAN study follows hundreds of families with inherited AD. The cohort includes people who carry presenilin and APP mutations, as well as their unaffected relatives. Previous studies in this cohort ...

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...

The latest effort to rewrite the diagnostic criteria for Alzheimer’s disease has stirred more than a little controversy. While the proposed revisions have garnered praise from researchers for more ...

All Signs Point to Plaque Clearance Tangle accumulation has slowed in all successful anti-amyloid antibody trials so far—except in the Trailblazer-Alz2 study of donanemab. That trial posted the ...